OMER Latest Headlines

Omeros Lands $2.1 Billion Deal with Novo Nordisk—Paves Way for New Treatments in Rare Blood and Kidney Disorders

Market Chameleon (Mon, 1-Dec 9:04 AM)

Omeros, Novo Nordisk close up to $2.1B deal for phase 2 asset zaltenibart

at seekingalpha.com (Mon, 1-Dec 9:18 AM)

Omeros Completes Major Asset Deal with Novo Nordisk

at www.tipranks.com (Mon, 1-Dec 9:01 AM)

Omeros Secures Up to $2.1 Billion in Novo Nordisk Deal for MASP-3 Inhibitor Zaltenibart—A Major Boost for Rare Disease Therapies

Market Chameleon (Wed, 15-Oct 9:53 AM)

Novo Nordisk Secures Global Rights to Omeros’ MASP-3 Inhibitor Zaltenibart—$2.1B Deal Sets Up Major Milestone for Rare Disease Treatment

Market Chameleon (Wed, 15-Oct 9:10 AM)